©2022 Stanford Medicine
Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection
Trial ID: NCT01326364
The purpose of this study is first, to determine whether baseline perfusion characteristics of pancreatic cancer, as characterized by CT perfusion studies, can predict tumor response to treatment by stereotactic body radiotherapy (SBRT). The second goal of this study is to determine whether baseline perfusion characteristics in those patients with resectable pancreatic cancer correlate with immunohistologic markers of angiogenesis such as microvessel density and vascular endothelial growth factor (VEGF) expression.
Prognostic Value of Baseline CT Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection
Brendan C. Visser, MD
Professor of Surgery (General Surgery)
George A. Poultsides, MD, MS, FACS
Professor of Surgery (General Surgery) at the Stanford University Medical Center
George A. Fisher Jr.
Colleen Haas Chair in the School of Medicine
Professor of Radiology (Cardiovascular Imaging)
1. suspected and/or biopsy-proven pancreatic adenocarcinoma, and
2. referral to Radiology for pre-treatment baseline pancreatic protocol CT.
1) are absolute contraindications to intravenous iodinated contrast or CT scan.
procedure: Stereotactic body radiotherapy
School of Medicine
300 Pasteur Drive
Stanford, CA 94305